Eliminating the X Factor
The Department of Health and Human Services has eliminated the X-waiver requirement for physicians who prescribe opioid addiction medicine. We...
How Healthcare Gets Extreme
Healthcare is a balance, weighing different causes and effects, like an internal opportunity cost. But when the law simplifies the...
The Vaccine Is Not The Savior We Believe – But That Is Okay
The vaccine has arrived and the roll-out has begun, with many of the high-risk already vaccinated. But we should remain...
Can India Do The Impossible?
Within days India will begin one of the largest vaccine roll-outs in the world. Despite the enormous challenges that lie...
Special Report: Amicus Curiae Brief (USA v. Walmart Inc.)
Healthcare litigation surrounding the opioid epidemic has led to a slew of high-profile legal cases - with implications extending throughout...
Experiencing COVID-19 Firsthand
While most of the world was relaxing over the holidays, we at Daily Remedy were struggling with COVID-19. And we...
Has COVID-19 Made Us Smarter?
Living through a pandemic has undoubtedly made us more aware of our health and healthcare policy. But as we struggle...
The Vaccine is Here
The vaccine is here - and everything seems to be going wrong. We discuss some of the obstacles encountered and...
COVID-19’s Mental Constraints
The pandemic has proven how complex the relationship between healthcare policy and economics can be. However, the mental constraints may...
Mindfulness in Medical Decisions
Healthcare is a series of decisions, one after another. But most decisions are made reflexively, reiterating familiar patterns of thought....
Water, Water Everywhere
The editors write a heartfelt note thanking the readers for their support of the healthcare content and for their participation...
Do the Previously Infected Need a Vaccine?
The vaccine roll-out is well on its way, and already the early rifts are starting to form. But the ensuing...
BIIB080 in Mild Alzheimer’s Disease: What a Phase 1b Exploratory Clinical Analysis Can—and Cannot—Tell Us
Can lowering tau biology translate into a clinically meaningful slowing of decline in people with early symptomatic Alzheimer’s disease? That is the practical question behind BIIB080, an intrathecal antisense therapy designed to reduce production of tau protein by targeting the tau gene transcript. In a phase 1b program originally designed for safety and dosing, investigators later examined cognitive, functional, and global outcomes as exploratory endpoints. The clinical question matters because current disease-modifying options primarily target amyloid, while tau pathology tracks...
Read more